May 2005
Worldwide Biotech;May2005, Vol. 17 Issue 5, p1
Trade Publication
Reports on a joint drug discovery program being pursued by the Global Alliance for TB Drug Development and GlaxoSmithKline to improve the treatment of tuberculosis (TB). Advantage of the program; Number of projects included in the joint research program; Goal of the TB Alliance.


Related Articles

  • GlaxoSmithKline Shortens R&D Cycle with JMP's Design of Experiments. Smith, Amy // Scientific Computing & Instrumentation;Oct2002, Vol. 19 Issue 11, p20 

    Explores the impact of statistical investigation of collected data on the drug development stage with reference to the experience of GlaxoSmithKline (GSK). Stages of drug development; Aim of GSK for shortened research and development cycle; Benefits of statistical investigation in drug development.

  • GSK'S Centres of Excellence for External Drug Discovery.  // Bio Outsourcing Asia;Mar2011, Vol. 3 Issue 4, p11 

    The article describes GlaxoSmithKline's (GSK) Centres of Excellence for External Drug Discovery (CEEDD). GSK's CEEDD is a pioneering team of about 25 people in GSK research and development tasked with forming multi-program, risk reward sharing alliances across all therapy areas. A CEEDD alliance...

  • Chroma Pact with GSK Carries $1B Potential.  // Bioworld Week;6/29/2009, Vol. 17 Issue 26, p4 

    The article offers information on the deal agreed between GlaxoSmithKline PLC (GSK) and Chroma Therapeutics Ltd. in Oxford, England. It is reported that Chroma got the contract worth $1 billion from GSK for the development of autoimmune and other inflammatory diseases treatments. Moreover,...

  • GSK-Funded Tempero Striking a Balance in Immune Response.  // Bioworld Week;5/2/2011, Vol. 19 Issue 18, p2 

    The article focuses on the Tempero Pharmaceuticals Inc. formed by GlaxoSmithKline PLC in an effort to carry a business plan for the creation of a target drug discovery platform. It states that Tempero works for a T-cell lineage that will play a role in inflammation and tissue damage. It mentions...

  • GSK backs patent pool for neglected diseases.  // Nature;2/19/2009, Vol. 457 Issue 7232, p949 

    The article discusses the decision by the pharmaceutical company GlaxoSmithKline (GSK) to share its patented knowledge regarding the development of medicines for neglected tropical diseases (NTDs), such as malaria and tuberculosis (TB), with drug companies, governments and nongovernmental...

  • The structure of Mycobacteria 2C-methyl-D-erythritol-2, 4-cyclodiphosphate synthase, an essential enzyme, provides a platform for drug discovery. Buetow, Lori; Brown, Amanda C.; Parish, Tanya; Hunter, William N. // BMC Structural Biology;2007, Vol. 7, p68 

    Background: The prevalence of tuberculosis, the prolonged and expensive treatment that this disease requires and an increase in drug resistance indicate an urgent need for new treatments. The 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid precursor biosynthesis is an attractive...

  • GSK, Emory Initiatives Address Translational Science Flaws. Powers, Marie // BioWorld Insight;6/17/2013, Vol. 21 Issue 25, p1 

    The article discusses the efforts of the research institutes for improving the efficiency of drug development. It mentions the Discovery Fast track competition, an initiative taken by the global health care company GlaxoSmithKline PLC, of providing funds and resources to research labs. It...

  • Competitor Analysis: Immunotherapy of Alzheimer's Disease.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article informs that Research & Markets Ltd. has added the report "Competitor Analysis: Immunotherapy of Alzheimer's Disease" report to their offering. The report provides a competitor analysis in the development pipeline of novel antibodies and vaccines for passive and active immunotherapy...

  • Fragment-Based Platform Lands Another Early Stage Astex Deal. Boggs, Jennifer // BioWorld Today;11/13/2009, Vol. 20 Issue 220, p1 

    The article reports on Astex Therapeutics Ltd.'s fragment chemistry-based discovery deal with GlaxoSmithKline plc (GSK). Under the agreement, GSK will pay Astex 20 million pounds up front, with another 37 million pounds milestone triggered very early in the discovery stages. Astex, on the other...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics